Thromboxane production in morbidly obese subjects

Area of Science:

• Cardiovascular Research
• Metabolic Syndrome
• Platelet Physiology

Background:

• Morbid obesity is paradoxically associated with less coronary atherosclerosis than obesity.
• Platelet activation, marked by thromboxane A2, is elevated in obesity, increasing cardiovascular risk.
• Data on thromboxane A2 in morbid obesity are scarce, necessitating investigation into its role in atherothrombotic burden.

Purpose of the Study:

• To investigate serum levels of thromboxane B2 (TxB2), high-sensitivity C-reactive protein (hs-CRP), and leptin in lean, obese, and morbidly obese subjects.
• To explore the relationship between these markers and body mass index (BMI), insulin sensitivity, and atherothrombotic burden.

Main Methods:

• Serum TxB2, hs-CRP, and leptin levels were measured in 17 lean, 25 obese, and 23 morbidly obese subjects without insulin resistance, diabetes, or cardiovascular disease.
• Subjects were categorized by BMI: lean (22.9 ± 1.6 kg/m²), obese (32.6 ± 2.4 kg/m²), and morbidly obese (48.6 ± 7.1 kg/m²).
• Statistical analyses were performed to compare marker levels and assess correlations with clinical parameters.

Main Results:

• Serum TxB2 levels were significantly lower in morbidly obese subjects compared to both lean and obese subjects (p < 0.001).
• Leptin and hs-CRP levels were elevated in obese and morbidly obese groups, correlating positively with BMI and waist circumference.
• TxB2 levels showed a negative correlation with leptin and BMI, while hs-CRP correlated with leptin and insulin resistance markers.

Conclusions:

• Insulin-sensitive morbidly obese subjects exhibit reduced platelet activation, evidenced by lower TxB2 levels.
• This diminished platelet activation may contribute to the paradoxical protection against atherosclerosis observed in morbidly obese individuals.
• The findings suggest that reduced atherothrombotic risk, despite elevated leptin, is linked to decreased platelet activity in morbid obesity.